| Drug Name |
Flunisolide hemihydrate |
| Drug ID |
BADD_D00921 |
| Description |
Flunisolide (marketed as AeroBid, Nasalide, Nasarel) is a corticosteroid with anti-inflammatory actions. It is often prescribed as treatment for allergic rhinitis and its principle mechanism of action involves activation of glucocorticoid receptors. |
| Indications and Usage |
For the maintenance treatment of asthma as a prophylactic therapy. |
| Marketing Status |
approved; investigational |
| ATC Code |
R01AD04; R03BA03 |
| DrugBank ID |
DB00180
|
| KEGG ID |
D00324; D04214
|
| MeSH ID |
C007734
|
| PubChem ID |
82153
|
| TTD Drug ID |
D0FM2P
|
| NDC Product Code |
46439-8740; 51927-1794; 50742-317; 24208-344 |
| UNII |
78M02AA8KF
|
| Synonyms |
flunisolide | flunisolide anhydrous | 6alpha-fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16, 17-acetal with acetone | 6 alpha-fluorodihydroxy-16 alpha,17 alpha-isopropylidenedioxy-1,4-pregnadiene-3,20- dione | flunisolide hemihydrate | flunisolide hemihydrate, (6alpha,11beta,16alpha)-isomer | Nasarel | AeroBid | Aerospan | RS-3999 | Nasalide | flunisolide acetate | RS-1320 | RS1320 | flunisolide 21-acetate | flunisolide, (6beta,11beta,16alpha)-isomer | ratio-Flunisolide | Rhinalar | Syntaris | flunisolide HFA | flunisolide hydrofluoroalkane | Apo-Flunisolide | Inhacort |
